## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($214.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Jefferies Adjusts Price Target on IQVIA Holdings to $270 From $255, Maintains Buy Rating**
- Source: MarketScreener | 20251202T110400 | Bullish | Relevance: 99%
- Jefferies has increased its price target on IQVIA Holdings to $270 from $255, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's financial prospects and market position. The article highlights recent analyst activities and insider transactions for IQVIA Holdings.

**2. IQVIA (NYSE: IQV) names AWS preferred agentic cloud to power new AI platform**
- Source: Stock Titan | 20251202T080000 | Bullish | Relevance: 99%
- IQVIA (NYSE: IQV) announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as its Preferred Agentic Cloud Provider. This partnership aims to revolutionize clinical trial automation, medical affairs, and analytics in life sciences by deploying IQVIA's AI platform on AWS. The collaboration seeks to democratize AI for life sciences, accelerate drug innovation, and improve patient outcomes globally.

**3. Morgan Stanley Raises Price Target on IQVIA Holdings to $265 From $250, Keeps Overweight Rating**
- Source: MarketScreener | 20251202T115200 | Bullish | Relevance: 99%
- Morgan Stanley has increased its price target for IQVIA Holdings (IQV) to $265 from $250, while maintaining an "Overweight" rating on the stock. This adjustment reflects continued positive sentiment from analysts towards the company, with other firms also recently raising their price targets. The article also provides key financial and operational details about IQVIA Holdings.

**4. IQVIA Holdings stock rating assumed at Overweight by Morgan Stanley**
- Source: Investing.com | 20251201T170500 | Bullish | Relevance: 98%
- Morgan Stanley initiated coverage on IQVIA Holdings (NYSE:IQV) with an Overweight rating and a price target of $265.00, suggesting a 16% upside. The firm anticipates strong demand for clinical research organization (CRO) work and highlighted IQVIA's leading position in diversified markets through its Technology & Analytics Solutions (TAS). This positive outlook is supported by recent upward revisions in earnings estimates by other analysts and the company's strong stock performance.

**5. IQVIA Holdings stock rating assumed at Overweight by Morgan Stanley**
- Source: Investing.com South Africa | 20251202T000600 | Bullish | Relevance: 98%
- Morgan Stanley has initiated coverage on IQVIA Holdings (NYSE:IQV) with an Overweight rating and a price target of $265.00, suggesting a 16% upside. This positive outlook is based on anticipated decent demand for clinical stage CRO work in 2026 and the company's strong performance, including a 63.91% price return over the past six months. Recent developments for IQVIA include exceeding third-quarter earnings expectations, the appointment of a Nobel laureate to its board, and varied analyst rating adjustments.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $5.8M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.95 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.0B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.95 |
| Forward P/E | 17.5 |
| Current P/E | 19.0 |
| YoY Growth | 8.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.1% to -2.2% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.25% (CS: 33) | Weak |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 0.26 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 1.071x | Above |
| vs SMA200 | 1.253x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $225.63
- **Stop Loss:** $214.53 (4.9% risk)
- **Target:** $236.73 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $20,306.70
- **Portfolio %:** 20.31%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*